Product Information
VEVYE 0.1% EYE DROP is a brand product labeled by Harrow Eye, LLC, priced at $379.8730 per ML under NDC 82667090002. Its NADAC has been published 120 times since Jun 19, 2024.
FDA first approved this application on May 30, 2023.
Strength
1 mg/mL
Manufacturer
Harrow Eye, LLCNDC
82667090002
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
7/1/2026
Active Ingredients
CYCLOSPORINEApproval Type
New Drug (NDA)
FDA Application
NDA217469FDA Approved
5/30/2023
On Market Since
12/1/2023
Pharmacological Classes
Price Statistics
The NADAC for VEVYE 0.1% EYE DROP has been published 120 times since Jun 19, 2024, and over the history we have for it it has risen 2.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $379.8730 per ML |
|---|---|
| All-time high | $379.8730 (Sep 30, 2026) |
| All-time low | $368.4729 (Jul 23, 2025) |
| 52-week high | $379.8730 |
| 52-week low | $368.5319 |
| Median price | $368.9526 |
| Average price | $370.4502 |
| Largest weekly change | +3.0% (Jul 1, 2026) |
| Weeks tracked | 120 |
| Tracking since | Jun 19, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cyclosporine ophthalmic solution market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Harrow Eye, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cyclosporine ophthalmic solution market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VEVYE 0.1% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for VEVYE 0.1% EYE DROP, manufactured by Harrow Eye, LLC, is $379.8730 per ML (NDC 82667090002), effective Sep 30, 2026.
How has the price of VEVYE 0.1% EYE DROP changed over time?
Over the history we have for it, the NADAC for VEVYE 0.1% EYE DROP has risen 2.5%. It has been tracked across 120 weekly CMS publications since Jun 19, 2024.
What are the highest and lowest recorded NADAC prices for VEVYE 0.1% EYE DROP?
Since Jun 19, 2024, the NADAC for VEVYE 0.1% EYE DROP has ranged from a low of $368.4729 (Jul 23, 2025) to a high of $379.8730 (Sep 30, 2026), with a median of $368.9526 per ML.
Are there cheaper alternatives to VEVYE 0.1% EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of VEVYE 0.1% EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VEVYE 0.1% EYE DROP?
VEVYE 0.1% EYE DROP (NDC 82667090002) is labeled by Harrow Eye, LLC, and CMS classifies it as a brand product.